Abcuro
Newton
About Abcuro
Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $414.8M
- Funding stage: Late Stage Venture
- Last round: Series C (Feb 2025)
- Website: abcuro.com
- Phone: (617) 714-9759
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/abcuro-104273 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.